Best Practice & Research Clinical Rheumatology
Volume 20, Issue 2 , Pages 279-300 , April 2006

Current management of juvenile idiopathic arthritis

  • Carol A. Wallace, MD (Associate Professor, Pediatrics)

      Affiliations

    • Corresponding Author InformationTel.: +1 206 987 4448; Fax: +1 206 987 5060.

References 

  1. Wallace CA, Ruperto N, Giannini EH, for the Childhood Arthritis and Rheumatology Research Alliance (CARRA) , the Pediatric Rheumatology InterNational Trials Organization (PRINTO) , Pediatric Rheumatology Collaborative Study Group (PRCSG) . Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis (JIA). The Journal Rheumatology. 2004;31:2290–2294
  2. Zak M, Pedersen FK. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford). 2000;39:198–204
  3. Minden K, Kiessling U, Listing J, et al. Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. The Journal Rheumatology. 2000;27:2256–2263
  4. Flato B, Lien G, Smerdel A, et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. The Journal Rheumatology. 2003;30(2):386–393
  5. Oen K, Malleson PN, Cabral DA, et al. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. The Journal Rheumatology. 2002;29(9):1989–1999
  6. Fantini F, Gerloni V, Gattinara M, et al. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. The Journal Rheumatology. 2003;30(3):579–584
  7. Gare BA, Fasth A. The natural history of juvenile chronic arthritis: a population based cohort study I. Onset and disease process. The Journal Rheumatology. 1995;22(2):295–307
  8. Bowyer SL, Roettcher PA, Higgins GC, et al. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. The Journal Rheumatology. 2003;30(2):394–400
  9. Guillaume S, Prieur AM, Coste J, Job-Deslandre C. Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis. Arthritis and Rheumatism. 2000;(43):1858–1865
  10. Lomater C, Gerloni V, Gattinara M, et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. The Journal Rheumatology. 2000;27:491–496
  11. Wallace CA, Huang B, Bandeira M, et al. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis and Rheumatism. 2005;52:3554–3562
  12. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford). 2002;41(12):1428–1435
  13. Arkela-Kautiainen M, Haapasaari J, Kautiainen H, et al. Favourable social functioning and health related quality of life of patients with JIA in early adulthood. Annals of the Rheumatic Diseases. 2005;64:875–880
  14. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: social function, relationships and sexual activity. Rheumatology (Oxford). 2002;41(12):1440–1443
  15. Ravelli A, Martini A. Early predictors of outcome in juvenile idiopathic arthritis. Clinical and Experimental Rheumatology. 2003;21(5 supplement 31):S89–S93
  16. Schneider R, Lang BA, Reilly BJ, et al. Prognostic indications of joint destruction in systemic-onset juvenile rheumatoid arthritis. The Journal of Pediatrics. 1991;120:200–205
  17. Zeggini E, Thomson W, Kwiatkowski D, et al. Linkage and association studies of single-nucleotide polymorphism-tagged tumor necrosis factor haplotypes in juvenile oligoarthritis. Arthritis and Rheumatism. 2002;46(12):3304–3311
  18. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity?. Arthritis and Rheumatism. 2002;46:283–285
  19. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis and Rheumatism. 2003;48(7):1771–1774
  20. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clinical and Experimental Rheumatology. 2003;21(5 supplement 31):S154–S157
  21. Moreland LW, Bridges SL. Early rheumatoid arthritis: a medical emergency?. The American Journal of Medicine. 2001;111:498–500
  22. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis and Rheumatism. 2000;43(1):22–29
  23. Mottonen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis and Rheumatism. 2002;46:894–898
  24. Breedveld FC, Emery P, Keystone E, et al. Infliximab in active early rheumatoid arthritis. Annals of the Rheumatic Diseases. 2004;63(2):149–155
  25. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Arthritis and Rheumatism. 2005;52:27–35
  26. van Vollenhoven RF, Ernestam S, Harju A, et al. Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. Arthritis Research and Therapy. 2003;5(6):R347–R351
  27. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis and Rheumatism. 2004;50(5):1400–1411
  28. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases. 2003;62(supplement 2):ii13–ii16
  29. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. The New England Journal of Medicine. 2000;343:1586–1593
  30. Genovese MC, Bathon JM, Fleischmann RM, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. The Journal of Rheumatology. 2005;32:1232–1242
  31. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parental methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis and Rheumatism. 2004;50:2191–2201
  32. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. The Journal of Rheumatology 2004;(10):2071–5.
  33. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. The Journal of Experimental Medicine 2005;(9):1479–86.
  34. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis and Rheumatism. 2005;52:818–825
  35. Gottlieb BS, Keenan GF, Lu T, Ilowite NT. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics. 1997;100(6):994–997
  36. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. The Journal of Clinical Investigation. 1993;92(6):2675–2682
  37. Thomas MH, Gutterman LA. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. The Journal of Rheumatology. 1986;13(2):440–441
  38. Frain JB. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. The Journal of Rheumatology. 1987;14(1):176–177
  39. Groenendal H, Rampen FH. Methotrexate and trimethoprim-sulphamethoxazole—a potentially hazardous combination. Clinical and Experimental Dermatology. 1990;15(5):358–360
  40. Wallace CA. The use of methotrexate in childhood rheumatic diseases. Arthritis and Rheumatism. 1998;41:381–391
  41. Ravelli A, Di Fuccia G, Molinaro M, et al. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. The Journal of Rheumatology. 1993;20:1573–1577
  42. Dupuis LL, Koren G, Silverman ED, Laxer RM. Influence of food on the bioavailability of oral methotrexate in children. The Journal of Rheumatology. 1995;22(8):1570–1573
  43. Wallace CA, Bleyer A, Sherry DD, et al. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis and Rheumatism. 1989;32:677–681
  44. Ravelli A, Migliavacca D, Viola S, et al. Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clinical and Experimental Rheumatology. 1999;17(5):625–627
  45. Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. The Journal of Rheumatology. 1998;25(1):36–43
  46. Cleary AG, McDowell H, Sills JA. Polyarticular juvenile idiopathic arthritis treated with methotrexate complicated by the development of non-Hodgkin's lymphoma. Archives of Disease in Childhood. 2002;86:47–49
  47. Bleyer WA. Methotrexate induced lymphoma?. Editorial Journal of Rheumatology. 1998;25:404–406
  48. Moder KG, Tefferi A, Cohen MD, et al. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective review. The American Journal of Medicine. 1995;99:276–282
  49. Ansell BM, Hall MA, Loftus JK, et al. A multicentre pilot study of sulphasalazine in juvenile chronic arthritis. Clinical and Experimental Rheumatology. 1991;9(2):201–203
  50. van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Arthritis Study Group. Arthritis and Rheumatism. 1998;41(5):808–816
  51. Huang JL, Chen LC. Sulphasalazine in the treatment of children with chronic arthritis. Clinical Rheumatology. 1998;17(5):359–363
  52. Varbanova BB, Dyankov ED. Sulphasalazine. An alternative drug for second-line treatment of juvenile chronic arthritis. Advances in Experimental Medicine and Biology. 1999;455:331–336
  53. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the USA–USSR double-blind placebo-controlled trial. The New England Journal of Medicine. 1986;314(20):1269–1276
  54. van Kerckhove C, Giannini EH, Lovell DJ. Temporal patterns of response to d-penicillamine, hydroxychloroquine, and placebo in juvenile rheumatoid arthritis patients. Arthritis and Rheumatism. 1988;31(10):1252–1258
  55. Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporin. The Journal of Pediatrics. 1996;128:275–278
  56. Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. The Journal of Pediatrics. 1996;129(5):750–754
  57. Savolainen HA, Kautiainen H, Isomaki H, et al. Azathioprine in patients with juvenile chronic arthritis: a long-term follow up study. The Journal of Rheumatology. 1997;4(12):2444–2450
  58. Lin YT, Yang YH, Tsai MJ, Chiang BL. Long-term effects of azathioprine therapy for juvenile rheumatoid arthritis. Journal of the Formosan Medical Association. 2000;99(4):330–335
  59. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group. The New England Journal of Medicine. 2000;342:763–769
  60. Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Annals of the Rheumatic Diseases. 2004;63(12):1638–1644
  61. Giannini EH, Lovell DJ, Ilowite NT, et al. Safety outcomes from a Phase IV pediatric registry: Etanercept (Enbrel) therapy in children and adolescents with juvenile rheumatoid arthritis (JRA). Arthritis and Rheumatism. 2004;50(supplement):S90
  62. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Annals of the Rheumatic Diseases. 2003;62(3):245–247
  63. Lovell DJ, Ruperto N, Goodman S, et al. Preliminary data from the study of adalimumab in children with juvenile idiopathic arthritis (JIA). Arthritis and Rheumatism. 2004;50(9):S436
  64. Keystone EC, Haraoui B, Bykerk VP. Role of adalimumab in the treatment of early rheumatoid arthritis. Clinical and Experimental Rheumatology. 2003;21(5 supplement 31):S198–S199
  65. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders. Prospects for anti-B cell therapy. Arthritis and Rheumatism. 2003;48:1484–1492
  66. Edwards JCW, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with Rituximab in patients with rheumatoid arthritis. The New England Journal of Medicine. 2004;350:2572–2581
  67. Panayi GS. B cell-directed therapy in rheumatoid arthritis—clinical experience. The Journal of Rheumatology. 2005;32(supplement 73):19–24(Abstract)
  68. Bearden CM, Agarwal A, Book BK, et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. American Journal of Transplantation. 2005;5:50–57
  69. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. The New England Journal of Medicine. 2005;353(11):1114–1123
  70. Gabay C. IL-1 trap. Regeneron/Novartis. Current Opinion in Investigational Drugs. 2003;4(5):593–597(Review)
  71. Cinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Current Opinion in Pharmacology. 2004;4(4):378–385(Review)
  72. Baslund B, Tvede N, Danneskoild-Samsoe B, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis and Rheumatism. 2005;52(9):2686–2692
  73. Kaltwasser JP, Behrens F. Leflunomide: long-term clinical experience and new uses. Expert Opinion on Pharmacotherapy. 2005;6(5):787–801
  74. van Roon EN, Hoekstra M, Tobi H, et al. Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation. France Journal of Clinical Pharmacology. 2005;60(3):319–325
  75. Silverman E, Mouy R, Spiegel L, et al. Leflunomide in juvenile rheumatoid arthritis (JRA) investigator group. Lefllunomide or methotrexate for juvenile rheumatoid arthritis. The New England Journal of Medicine. 2005;352(16):1655–1666
  76. Wallace CA, Sherry DD. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis and Rheumatism. 1997;40(10):1852–1855
  77. Chen CY, Chen LC, Yeh KW, et al. Sequential changes to clinical parameters and adhesion molecules following intravenous pulse cyclophosphamide and methylprednisolone treatment of refractory juvenile idiopathic arthritis. Clinical and Experimental Ophthalmology. 2004;22(2):259–264
  78. Lehman TJ, Schechter SJ, Sundel RP, et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. The Journal of Pediatrics. 2004;146(6):856–857
  79. De Kleer IM, Brinkman DM, Ferster A, et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Annals of the Rheumatic Diseases. 2004;63(10):1318–1326
  80. Wulffraat NM, Vastert B, Tyndall A. Treatment of refractory autoimmune diseases with autologous stem cell transplantation: focus on juvenile idiopathic arthritis. Bone Marrow Transplantation. 2005;35(supplement 1):S27–S29

PII: S1521-6942(05)00131-2

doi: 10.1016/j.berh.2005.11.008

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 2 , Pages 279-300 , April 2006

Article Tools

* Image Usage & Resolution